SCHEDULE: Former Cyclacel CEO Sells Shares, Amends 13D Filing
Beneficial Ownership Amendment
Former Cyclacel Pharmaceuticals CEO David E. Lazar disclosed significant share sales and updated his beneficial ownership in an amended Schedule 13D filing.
Summary
- This filing is Amendment No. 1 to the Schedule 13D previously filed by David E. Lazar regarding his interest in Cyclacel Pharmaceuticals, Inc. Common Stock.
- David E. Lazar resigned as Chief Executive Officer of Cyclacel Pharmaceuticals, Inc. effective April 2, 2025.
- As of August 1, 2025, David E. Lazar beneficially owned 129,629 shares of Common Stock, representing approximately 8.18% of the 1,583,965 shares outstanding as of July 10, 2025.
- The reported share count reflects a 1-for-15 reverse stock split effected by the Issuer on July 7, 2025.
- On February 26, 2025, David E. Lazar converted Preferred Stock into Common Stock and sold 194,628,820 shares of Common Stock (pre-reverse split) to a third-party investor in a private transaction.
- The amendment corrects a ministerial error in the original Schedule 13D regarding the number of Series D Preferred Stock shares retained after the February 26, 2025 sale.
- Transactions in the past sixty days include sales of 6,750 shares at $12.36 on July 30, 2025; 15,000 shares at $11.68 on July 31, 2025; and 10.22 shares at $10.22 on August 1, 2025.
Sentiment
Score: 3
Explanation: The sentiment is negative due to the significant insider selling by the former CEO and the correction of a prior reporting error, which can erode investor confidence.
Negatives
- The former CEO, David E. Lazar, engaged in significant share sales, including 194,628,820 shares (pre-split) in February 2025 and additional sales in late July/early August 2025.
- The filing notes a 'ministerial error' in the original Schedule 13D regarding previously reported retained shares, which could indicate a lack of precision in prior disclosures.
Future Outlook
No forward-looking statements or guidance are provided in this beneficial ownership amendment.
Industry Context
This filing is a specific disclosure of an individual's beneficial ownership and past transactions, including a former CEO's resignation and share sales. It does not provide information on broader industry trends or competitive landscape.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Chief Executive Officer | David E. Lazar | 04/02/2025 | Resignation |
Stakeholder Impact
- Shareholders may view the significant insider selling by a former CEO as a negative signal regarding the company's future prospects or valuation.
- The correction of a 'ministerial error' in a prior filing could raise questions among investors about the accuracy and reliability of company disclosures.
Key Dates
| Date | Description |
|---|---|
| 02/26/2025 | Reporting Person converted Preferred Stock into Common Stock and sold 194,628,820 shares (pre-reverse split) to a third party. |
| 04/02/2025 | David E. Lazar resigned as Chief Executive Officer of the Issuer. |
| 07/07/2025 | Issuer effected a 1-for-15 reverse stock split. |
| 07/10/2025 | 1,583,965 shares of Common Stock outstanding as reported in the Issuer's Form S-1. |
| 07/30/2025 | Date of event requiring filing of this statement; Sale of 6,750 shares at $12.36. |
| 07/31/2025 | Sale of 15,000 shares at $11.68. |
| 08/01/2025 | Sale of 10.22 shares at $10.22; Reporting Person beneficially owned 129,629 shares as of close of business. |
| 08/04/2025 | Date of signature for the Schedule 13D Amendment. |
Recommendation
sellThe substantial share sales by the former CEO, David E. Lazar, particularly the large private transaction and subsequent market sales, indicate a lack of confidence from a key insider. This, combined with his resignation, presents a strong negative signal for the stock, suggesting potential downward pressure or limited upside.
Keywords
Cyclacel Pharmaceuticals, David E. Lazar, Schedule 13D, Beneficial Ownership, Common Stock, Reverse Stock Split, CEO Resignation, Insider Selling, Share Sale
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.